Insulin Secretagogues

Clinical Diabetes

Volumn , Issue , 2006, Pages 293-304

  Smith, Tamar ^a   Gerich, John E ^b,c  

^a Franklin Square Hospital Center ^*  (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846550572     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0273-4.50028-X     Document Type: Chapter

References (80)

1. Gerich JE Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 2003, 78:447-456.
2. Gerich J The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998, 19:491-503.
3. Pimenta W, Kortytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. JAMA 1995, 273:1855-1861.
4. Vaag A, Henriksen J, Madsbad S, et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 1995, 95:690-698.
5. Van Haeften T, Pimenta W, Mitrakou A, et al. Relative contributions of β-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 2000, 49:1318-1325.
6. van Haeften TW, Pimenta W, Mitrakou A, et al. Disturbances in beta-cell function in impaired fasting glycemia. Diabetes 2002, 51(Suppl 1):S265-S270.
7. U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995, 44:1249-1258. UK Prospective Diabetes Study Group.
8. Iozzo P, Beck-Nielsen H, Laakso M, et al. Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab 1999, 84:863-868.
9. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
10. Pratley R, Weyer C The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001, 44:929-945.
11. Polonsky K, Sturis J, Bell G Noninsulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996, 334:777-783.
12. Janbon M, Chaptal J, Vedel A, et al. Accidents hypoglycemiques graves par un sulfamido-thiadiazol (le VK57 ou 2254 RP). Montpellier Med 1942, 441:21-22.
13. Loubatieres A Relations entre la structure moleculaire et l'activité hypoglycemiante des aminosulfamides hypogly-cemiantes. Arch Int Physiol 1944, 54:174-177.
14. Loubatieres A Relation de mechanisme de l'action hypoglycemiante du p-aminobenzene-sulfamido-isopropylthiazol (2254RP). Compt Rend Soc Biol 1944, 138:766-767.
15. Loubatieres A Etude physiologique et pharmacodynamique de certaens derives solfamides hypoglyceminants. Arch Int Physiol 1946, 54:174-177.
16. Grunberger G, Ryan J, Gorden P Sulfonylureas do not affect insulin binding or glycemic control in insulin-dependent diabetics. Diabetes 1982, 31:890-896.
17. Ratzmann KP, Schulz B, Heinke P, et al. Tolbutamide does not alter insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia 1984, 27:8-12.
18. Keller U, Muller R, Berger W Sulfonylurea therapy fails to diminish insulin resistance in type I diabetic subjects. Horm Metab Res 1986, 18:599-603.
19. Kajinuma H, Kuzuya TT, Ide T Effects of hypoglycemic sulfonamides on glucagon and insulin secretion in ducks and dogs. Diabetes 1974, 23:412-417.
20. Tsalikian E, Dunphy T, Bohannon N, et al. The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal. Diabetes 1977, 26:314-321.
21. Gerich J Oral hypoglycemic agents. N Engl J Med 1989, 321:1231-1245.
22. Dunn C, Faulds D Nateglinide. Drugs 2000, 60:607-615.
23. Culy CR, Jarvis B Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001, 61:1625-1660.
24. ATP channel. J Membr Biol 2000, 176:187-206.
25. Seino S ATP-sensitive potassium channels: A model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999, 61:337-362.
26. Gribble FM, Ashcroft FM Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000, 49:3-6.
27. ATP channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000, 293:444-452.
28. + channel in insulin-secreting cells. J Biol Chem 1987, 262:15840-15844.
29. Gaines KL, Hamilton S, Boyd AE Characterization of the sulfonylurea receptor on beta cell membranes. J Biol Chem 1988, 263:2589-2592.
30. Grodsky GM, Epstein GH, Fanska R, et al. Pancreatic action of the sulfonylureas. Fed Proc 1977, 36:2714-2719.
31. Hu S, Boettcher BR, Dunning BE The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 2003, 46(Suppl 1):M37-M43.
32. Korytkowski M, Thomas A, Reid L, et al. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002, 25:1607-1611.
33. Schade D, Jovanovic L, Schneider J A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998, 38:636-641.
34. Brogden R, Heel R, Pakes G, et al. Glipizide: A review of its pharmacologic properties and therapeutic use. Drugs 1979, 18:329-353.
35. Balant L Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 1981, 6:215-241.
36. Langtry H, Balfour J Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998, 55:563-584.
37. Hasslacher C Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003, 26:886-891.
38. McLeod JF Clinical pharmacokinetics of nateglinide: A rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004, 43:97-120.
39. Jackson JE, Bressler R Clinical pharmacology of sulphonylurea hypoglycaemic agents: Part 1. Drugs 1981, 22:211-245.
40. Jackson JE, Bressler R Clinical pharmacology of sulphonylurea hypoglycaemic agents: Part 2. Drugs 1981, 22:295-320.
41. Chung M, Kourides I, Canovatchel W, et al. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. J Clin Pharmacol 2002, 42:651-657.
42. Balant L, Zahnd GR, Weber F, et al. Behaviour of gliben-clamide on repeated administration to diabetic patients. Eur J Clin Pharmacol 1977, 11:19-25.
43. Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997, 20:597-606.
44. Fuccella LM, Tamassia V, Valzelli G Metabolism and kinetics of the hypoglycemic agent glipizide in man-comparison with glibenclamide. J Clin Pharmacol New Drugs 1973, 13:68-75.
45. Pearson JG, Antal EJ, Raehl CL, et al. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 1986, 39:318-324.
46. Balant L, Fabre J, Loutan L, et al. Does 4- trans-hydroxy-glibenclamide show hypoglycemic activity?. Arzneimit-telforschung 1979, 29:162-163.
47. Rupp W, Christ O, Fulberth W [Studies on the bioavailability of glibenclamide]. Arzneimittelforschung 1972, 22:471-473.
48. Fabre J, Balant L, Loutan L, Samimi H Hypoglycemic activity of the main metabolite of glibenclamide: Influence of renal insufficiency [abstract]. Kidney Int 1978, 13:435.
49. Balant L, Zahnd G, Gorgia A, et al. Pharmacokinetics of glipizide in man: Influence of renal insufficiency. Diabetologia 1973, 9:331-338.
50. DeFronzo R Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
51. Inzucchi S Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA 2002, 287:360-372.
52. Kitabchi AE, Kaminska E, Fisher JN, et al. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am J Med Sci 2000, 319:143-148.
53. Dills DG, Schneider J Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996, 28:426-429.
54. Jovanovic L, Dailey G, Huang W-C, et al. Repaglinide in type 2 diabetes: A 24-week fixed-dose efficacy and safety study. J Clin Pharmacol 2000, 40:49-57.
55. Goldberg R, Einhorn D, Lucas C, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998, 21:1897-1903.
56. Hanefeld M, Bouter KP, Dickinson S, et al. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000, 23:202-207.
57. Horton E, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000, 23:1660-1665.
58. Marbury T, Huang W, Strange P, et al. Repaglinide versus glyburide: A one-year comparison trial. Diabetes Res Clin Pract 1999, 43:155-166.
59. Landgraf R, Bilo H, Müller P A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999, 55:165-171.
60. Wolffenbuttel B, Landgraf R A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999, 22:463-467.
61. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999, 22:119-124.
62. Hollander P, Schwartz S, Gatlin M, et al. Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001, 24:983-988.
63. Woerle HJ, Pimenta W, Meyer C, et al. Diagnostic and therapeutic implications of relationships between fasting, 2 hour postchallenge plasma glucose and HbA1c values. Arch Intern Med 2004, 164:1627-1632.
64. UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995, 44:1249-1258. UK Prospective Diabetes Study Group.
65. Horton ES, Foley JE, Shen SG, et al. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2004, 20:883-889.
66. Riddle MC, Schneider J Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998, 21:1052-1057.
67. Krentz AJ, Ferner RE, Bailey CJ Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994, 11:223-241.
68. Weitgasser R, Lechleitner M, Luger A, et al. Effects of glimepiride on HbA(1c) and body weight in type 2 diabetes: Results of a 1.5-year follow-up study. Diabetes Res Clin Pract 2003, 61:13-19.
69. Welle S, Nau S, Lockwood D Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes. J Clin Endo Metab 1988, 66:593-597.
70. Berger W Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res 1985, 17(Suppl 15):111-115.
71. Campbell I Metformin and the sulfonylureas: The comparative risk. Horm Metab Res 1985, 17(Suppl 15):105-111.
72. Campbell IW Hypoglycaemia and type 2 diabetes: Sulphonylureas. Hypoglycaemia and diabetes 1993, 387-392. Edward Arnold, London. B.M. Frier, B.M. Fisher (Eds.).
73. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310:83-88. United Kingdom Prospective Diabetes Study (UKPDS). 13.
74. Holstein A, Plaschke A, Egberts E-H Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17:467-473.
75. Kadowaki T, Hagura R, Kajinuma H, et al. Chlorpropamide-induced hyponatremia: Incidence and risk factors. Diabetes Care 1983, 6:468-471.
76. Sloan RW, Kreider RM, Luderer JR The effect of chlorpropamide hyponatremia on mental status in a nursing home population. J Fam Pract 1983, 16:937-942.
77. Hatorp V, Hansen KT, Thomsen MS Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003, 43:649-660.
78. Postprandial blood glucose. Diabetes Care 2001, 24:775-778. American Diabetes Association.
79. Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfi-brozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: Potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003, 46:347-351.
80. Niemi M, Neuvonen M, Juntti-Patinen L, et al. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clin Pharmacol Ther 2003, 74:25-31.